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Research Article
Composite Three-Marker Assay for Early Detection of Kidney
Cancer
Dong Su Kim1, Young Deuk Choi3, Mihyang Moon1, Suki Kang2, Jong-Baeck Lim4, Kyung Min Kim1,
Kyung Mok Park5, and Nam Hoon Cho2
Abstract
Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging.
To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay
composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein
(NM23A) was evaluated.
Methods: Patients with kidney cancer and control group were included in the clinical evaluation.
Participants were divided into cohorts representing the training group of control group including healthy
and benign tumors (n ¼ 102) and patients with kidney cancer (n ¼ 87) that were used to identify criteria for
scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n¼
100). A scoringmethod based on the cut-point of each of the threemarkers was used to evaluate the diagnostic
performance of the marker combination.
Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer
(P < 0.0001). In 289 blind sample tests with control subjects (n¼ 175) and patients with kidney cancer (n¼ 114),
the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When
90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%,
respectively. The predictive value of the three-marker assay was 87.2% (þPPV) and 97% (PPV).
Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker
assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic
characteristics.
Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.
Cancer Epidemiol Biomarkers Prev; 22(3); 390–8. 2013 AACR.
Introduction
Renal cell carcinoma (RCC) is the most commonmalig-
nancy of the adult kidney and the third most common
urologic malignancy, representing approximately 2% of
all malignancies and 2% of cancer-related deaths world-
wide (1). RCC is a clinicopathologically heterogeneous
disease that is traditionally subdivided on the basis of
morphologic features into clear cell, papillary, chromo-
phobe, collecting duct carcinoma, unclassified renal cell
carcinoma, metanephric adenoma, papillary adenoma,
and renal oncocytoma according to the World Health
Organization (WHO) International Histological Classifi-
cation of Kidney Tumors (2, 3). Subtypes of RCC classified
on the basis of cytogenetic features have been correlated
with biologic behavior. The clear cell subtype of RCC, the
most common subtype, is often associated with loss of
chromosome 3p harboring the von Hippel–Lindau tumor
suppressor gene and, together with papillary carcinoma,
manifests the worst clinical course, whereas the less com-
mon subtype of chromophobe RCC exhibits a muchmore
indolent clinical course (4, 5). Because of the lack of
curative therapy and highmetastasis rate of up to approx-
imately 30% overall and 15% to 25% even at presentation,
RCC is one of the most refractory malignancies and is
highly resistant to conventional chemotherapy and radi-
ation therapy (5, 6).
The incidence of RCC is increasing and it is most
prevalent in developed countries, probably due to a com-
bination of environmental factors and the increasing use
of imaging modalities leading to increased detection. In
general, corporal imaging methods including X-rays, CT
scans, and ultrasonography, are currently used for initial
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diagnosis of RCC, which is subsequently confirmed by
histologic analysis. These modalities have limitations for
distinguishing the various types of RCC and are some-
times slowand labor intensive. In addition, asymptomatic
RCC could be a leading cause of failed early detection of
kidney cancer. Despite significant progress in themedical
treatment of metastatic RCC, nephrectomy remains the
only effective treatment for localized RCC (7). However,
no clinically relevant screening assay is currently avail-
able to detect asymptomatic RCC (8) and there is, there-
fore, an urgent need for validated markers of RCC. In a
previous study, we reported the identification and veri-
fication of several markers for early detection of RCC and
suggested their potential as promising candidatemarkers
for early detection of RCC (9). Among these markers, N-
methyltransferase (NNMT), L-plastin (LCP1), and non-
metastatic cells 1 protein (NM23A) are explored in the
present study. This study is an investigation with the
following aims: (i) to evaluate the diagnostic potential of
these serum/plasma markers, (ii) to develop a feasible
multiplex assay for composite markers, and (iii) to eval-
uate the analytical performance and validate the clinical
performance.
Material and Methods
Clinical samples
Blood samples were obtained at the Yonsei University
College of Medicine (Seoul, Republic of Korea) after
obtaining written informed consent and under the Insti-
tutional Review Board-approved protocols of investiga-
tion (4–2008–0071).Demographyofparticipantswas sum-
marized in Table 1. Patient samples were collected from
114 cases who were diagnosed with kidney cancer using
imaging modalities and confirmed by cytopathologic
analysis. Control group (n ¼ 175) was composed of sam-
ples of healthy individual and samples with benign
tumors. Samples from healthy population (n ¼ 160) were
obtained from the Department of Diagnostic Laboratory
Medicine, YonseiUniversityCollege ofMedicine (n¼ 120)
and fromRedCross DaeguGyeongbuk Blood Center (n¼
40). Early collections (n ¼ 189) were used for the training
group study and the later collections (n ¼ 100) were used
in blinded validation of the criteria used for markers that
were previously developed with the training group.
Sample preparation
A venous blood sample was drawn from each subject
into 5 mL sterile vacutainer tube containing 4 mg K2
EDTA, and the tube was inverted carefully 10 times to
mix blood and anticoagulant. Mixed blood sample with
anticoagulant was then centrifuged immediately at 2,500
rpm for 20 minutes. The plasma supernatant was divided
into 3 aliquots and stored at 80C.
Conjugation of antibody to beads
Recombinant protein calibrator, antibody prepara-
tion, and biotin labeling of detection antibodies was car-
ried out with the procedures as previously described (9).
Briefly, recombinant protein was prepared from full-
length cDNA for NNMT (GeneBank accession num-
ber: NM_006169), LCP1 (GeneBank accession number:
NM_002298.4), and NM23A (GeneBank accession
Table 1. Demography of participants
Combined total (n ¼ 289) Training Group (n ¼ 189) Test group (n ¼ 100)
Control (n ¼ 175) Control (n ¼ 102) Control (n ¼ 73)
Healthy (n ¼ 160) 90 (88%) 70 (96%)
Renal oncocytoma (n ¼ 6) 4 (4%) 2 (3%)
Benign (n ¼ 9) 8 (8%) 1 (1%)
Sex Male Female Age Median
139 (79%) 36 (21%) 39
Kidney cancer (n ¼ 114) Kidney cancer (n ¼ 87) Kidney cancer (n ¼ 27)
Sex Male Female Age Median
73 (60%) 41 (36%) 50.9
Cell type Cell type pT Stage Cell type pT Stage
Ia/Ib II IIIa/IIIb IV Ia/Ib IIa/IIb IIIa/IIIb IV
Clear cell RCC (n ¼ 89) 66 (75%) 39 9 18 23 (88%) 12 1 9 1
Papillary RCC (n ¼ 6) 6 (7%) 3 1 1 1
Chromophobe RCC (n ¼ 7) 6 (7%) 4 1 1 1 (4%) 1
TCC (transitional Cell Carcinoma) (n ¼ 9) 8 (9%) 1 (4%)
Unclassiﬁed RCC (n ¼ 3) 1 (1%) 1 2 (8%)
Total 46 (52%) 12 (14%) 20 (23%) 1 (1%) 13 (50%) 1 (4%) 9 (35%) 1 (4%)
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number: NM_198175.1). Antibodies were conjugated to
beads (Luminex Corp.) as follows: anti-NNMT IgG was
conjugated to bead 63, anti-LCP1 IgG was conjugated to
bead 17, and anti-NM23A was conjugated to bead 33.
Conjugation of antibody to carboxy-coated beads was
carried out according to the manufacturer’s instruction.
In brief, 1  106 beads were washed twice by centrifu-
gation with deionized water and resuspended in 8 mL of
sodium phosphate buffer (pH 6.2) by vortexing and
sonication. Each 4 mL solutions of N-hydroxysulfosuc-
cinimide (sulfo-NHS; Thermo Scientific) and 1-ethyl-3
(3-dimethylaminopropyl)-carbodiimide hydrochloride
(EDC; Sigma) was added to the beads suspension and
mixed gently by vortexing. After incubation for 20
minutes at room temperature, beads were washed twice
with 50 mL coupling solution (50 mmol/L MES), and
resulting bead pellet was resuspended with 20 mL of
the same solution. Diluted 10 mg of antibody solution
(1 mg/mL) was added to resuspended beads and the
volume was adjusted to 100 mL with coupling solution.
Coupling of antibody was carried out by incubating for
2 hours at room temperature with rotation and washed
twice with 200 mL of storage/coupling solution (PBS
containing 0.1% BSA, 0.05% Tween 20, 0.05% sodium
azide). Resuspended antibody-conjugated beads in 100
mL of storage solution were counted by hemocytometer
and stored at 2 to 8C (in dark)
Multiplexed microsphere immunoassay
All assayswere developed and validated as bead-based
sandwich immunoassays using bead-conjugated capture
antibodies, biotin-labeled detection antibodies, and phy-
coerythrin-labeled streptavidin (Invitrogen). Assay was
done infilterplate (MilliporeCorporation) prewettedwith
assay buffer [100 mmol/L Tris HCl pH 7.4, 150 mmol/L
NaCl, 1% bovine serum albumin (BSA), 2mmol/L EDTA,
2% polyethylene glycol 4000, 1.2% Synperonic F68, 0.1%
sodium azide, and 0.2 mg/mL rabbit IgG)] at room tem-
perature and in dark by covering the lid of filterplate. All
incubations in the assaywere done by shaking at 400 rpm.
Solution drain and washing step was done with vacuum
manifold (Millipore). Recombinant protein calibrators
were used to evaluate xMAP setup. Bovine plasma was
used as adilutionmatrix of calibrator as amimic of human
plasma samples. Before multiplexed assay setup, each
single-analyte assay was evaluated separately and pair-
wise addition of bead-conjugated capture antibody was
conducted. Consistency or changes of calibration curve in
subsequent addition of capture antibodywas observed. If
there was any change in the calibration curve, it was
adjusted and optimized by incorporating a set of blocking
condition against nonspecific binding of each antibody
pairs. Twenty microliters of assay buffer containing 1,000
capture antibody-conjugated beadswas transferred to the
filterplate and 20mLof plasma samples or calibratorswere
added.After 30-minute incubation, 10mLof biotin-labeled
detection antibody (160 mg/mL) dilutedwith assay buffer
was added and incubated for additional 30minutes. After
three timeswashing eachwith 100mLofwashing solution
(50 mmol/L Tris HCl pH 7.4, 150 mmol/LNaCl, 1% BSA,
0.1% sodium azide, 0.05% Tween 20), 50 mL of phyco-
erythrin-labeled streptavidin (PE,4 mg/mL) in PE solu-
tion was added and incubated for 30 minutes. Without
wash, 50-mLPEsolutionwasaddedandbeadsweremixed
thoroughly before reading on Luminex100 system (Lumi-
nex Corp.) using MasterPlex CT software (Ver. 1.0; Mir-
aiBio, Inc.). The data were processed and analyzed using
MasterPlex QT software with linear regression curves.
Analytical assay validation
On the basis of guidelines from the International Med-
icalDeviceRegulators Forum (10), analytical performance
of 3-plex assay (NNMT, LCP1, and NM23A) was validat-
ed. Validation of analytical performance included the
assessment of accuracy of measurement, analytical sen-
sitivity, analytical specificity, measuring range, and lin-
earity of assay. Trueness of accuracy was assessed by
measuring the recovery of contrived samples. The con-
centration of recombinant analytes (markers) spiked with
pooled human normal plasma was measured at high,
middle, and low concentration of measuring range. Pre-
cision of accuracy was also tested. Repeatability was
estimated as within-run variability with calibrators in
standardmatrix or humanplasma and expressed in terms
of coefficient of variation (CV%). Reproducibility was an
estimation of between-run variability (CV%) of assays
over 3 days. Limit of detection (LoD) and limit of quan-
tification (LoQ) was included to evaluate the analytical
sensitivity. LoD was calculated by adding 3 SDs to mean
concentration of 17 replicates of blankmatrix. LLoQ (Low
LoQ)was estimated by calculating the concentration of 17
replicates of full range of calibrators ranging from 33 to
24,000 pg/mL (NNMT), 123 to 90,000 pg/mL (LCP1), and
33 to 24,000 (NM23A). LLoQwasdetermined at the lowest
concentration at which precision and bias was within
specified criteria. The criteria for acceptance of LLoQwere
%CV < 20 and %RE (relative error) < 20. Analytic
specificitywas tested using human serum, EDTA-plasma,
and citrate plasma. Samples from 8 healthy persons were
used to assess the exogenous effect of anticoagulant in
plasma preparation. Linearity of dilutionwas assessed by
diluting calibrators in human plasma with matrix in a
series of seven 3-fold dilution for all 3-plex panels. Lin-
earity of calibrator curve was assessed with linear-regres-
sion system, and measuring range of 3-plex panels was
adjusted to the concentration within the linearity of
accepted criteria (R2 > 0.997). Linearity of dilution was
also assessed with pooled normal plasma samples (n¼ 8)
with the same range of calibrator curve, and the slopewas
compared with that from standard matrix.
Data analysis
Statistical analyses were carried out using MedCalc
software (Ver.9.6.4.0; ref. 11). Linear regression was used
to generate calibration curve, and Pearson correlation
coefficient (R2) was used to assess the linearity of curves.
Kim et al.
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Mann–Whitney test (independent samples) was used to
assess the significance of difference in plasma marker
concentration between control group and kidney tumor.
Logistic regression analysis with 3 markers was used to
differentiate predicted probability on the presence of
tumor. Stepwise logistic regression with the 3 tumor
markers of 3-plex panel was conducted and the predicted
probability was used to compare with the diagnostic
performance of each marker. Receiver operating charac-
teristic (ROC) curve analysis was used to generate the
value of specificity, sensitivity, and area under curve
(AUC). Scoring system was also applied to facilitate the
diagnostic prediction of 3-panel kidney tumor markers.
Scoring was carried out with the procedure for best cut-
point determination and assignment of the score to the
sample tested. The best cut-points were selected at
the point of highest Youden Index of each marker from
the ROC analysis of training group samples with the
cohort of control (n ¼ 102) and cancer (n ¼ 87) donors.
The cut-points were the concentration of each marker at
the associated criterion of the highest Youden Index from
ROC analysis usingMedCalc software. On the basis of the
plasma concentration of markers, individual was
assigned score 0 ( cut-point) or 1 (>cut-point) for each
marker and finally assigned a score ranging from 0 to 3 as
the sum of 3 markers.
Results
Validation of analytical performance
We plan to develop multiplexed assay including
NNMT, LCP1, and NM23A and developed highly sensi-
tive bead based-multiplexed assay (3-plex). Analytic per-
formance of 3-plex assay was programmed and validated
to be accurate with high sensitivity and precision (see
Supplementary data).
Trueness of accuracy was assessed by measuring the
mean recovery of contrived samples with the acceptance
criteria within 10%. The concentration of recombinant
analytes (NNMT,NM23A, and LCP1) spikedwith pooled
normal human plasma was measured and recovery was
calculated. For example, recovery of NNMT at high
(24,000 pg/mL), middle (2,667 pg/mL), and low concen-
tration (296pg/mL)wasmeasured and themean recovery
was 100.1% (98.5–101.1%), 105.9% (90.3–120.5%), and
101.4% (82.1–125.1%), respectively. Analytical perfor-
mance ofmean recovery for 3-plex assay ofNNMT, LCP1,
and NM23A was within 10% at all 3 low, middle, and
high concentrations. Acceptance criteria for within- and
between-run variability were below 20% (CV). Precision
of repeatability (within-run variability) was within 1.0 to
19.1% (CV) and reproducibility (between-run variability)
with 3-plex assays over 3 days was within 0.7 to 15.9%
(CV). Precision of repeatability in calibrator’s matrix (2.3–
19.0% CV) and human plasma (1.0–19.1% CV) was com-
parable. However, it could not be excluded that there are
molecules interfering specific binding of markers in
human plasma samples and causing increased uncertain-
ties of concentration. Analytical sensitivity assessed by
estimation of LoD and LLoQ showed that 3-plex assay is
highly sensitive. Estimated LoD for NNMT, LCP1, and
NM23A was 1.6 pg/mL, 89.5 pg/mL, and 61.1 pg/mL,
respectively. On the basis of the acceptance criteria of
precision (%CV < 20) and bias (%RE < 20) of markers,
LLoQwas determined at each range of calibrator of 3-plex
assay. LLoQ ofNNMT, LCP1, andNM23Awas estimated
at 33, 370, and 99 pg/mL, respectively, and these con-
centrations were equivalent to calibrator1 of NNMT,
calibrator2 of LCP1, and calibrator2 of NM23A, respec-
tively. Then, the lowest standard of LCP1 and NM23A
could not be used to quantify sample concentration. For
evaluation of analytic specificity, interference of antico-
agulant in plasma preparation was estimated. Mean var-
iability (acceptance criterion, CV < 10%) on recovery of an
analyte in EDTA-plasma (NNMT: 93.6%–104.2%, LCP1:
90.6%–117.6%, and NM23A: 90.8%–117.5%) and citrated-
plasma (NNMT: 87.2–114.5%, LCP1: 83.5%–115.8%, and
NM23A: 85.7%–106.3%) compared with serum samples
was within 10%. It was comparable with the precision of
repeatability of 3-plex assay, although the recovery of
NM23A in EDTA-plasma compared with serum sample
(CV¼ 10.1%) did not pass the acceptance criterion. For the
interpretation of linearity of dilution, calibrator in human
plasma was measured. The linearity of dilution of 3
markers of NNMT, LCP1, and NM23A with pooled
human plasma was more than 0.997 and the slope with
standard matrix was comparable with that of human
plasma (see Supplementary Data) within the concentra-
tion range of 46 to 24,173 pg/mL (NNMT, R2 ¼ 0.9999),
14,711 to 110,877 pg/mL (LCP1, R2 ¼ 0.9997), and 500 to
25,436 pg/mL (NM23A, R2 ¼ 1).
Differential plasma concentrations of NNMT, LCP1,
and NM23A between kidney cancer patients and
control individuals
Using the 3-plex assay, plasma concentrations of
NNMT, LCP1, andNM23Aweremeasured in 189 plasma
samples from 102 control individuals and 87 patients
with kidney cancer of pathologic stages I to IV and used
to evaluate their potential as biomarkers for kidney
cancer. As shown in Fig. 1 and Table 2, these 3 markers
were detected in most of the plasma samples and were
highly elevated in patients with kidney cancer. Themedi-
an NNMT concentration in control individuals was 68
pg/mL compared with 420 pg/mL for patients with
kidney cancer. This difference was found to be significant
(P < 0.0001) by the Mann–Whitney test (independent
samples). The diagnostic performance or the accuracy of
theNNMTassay to discriminate kidney cancer cases from
control case was evaluated using the ROC curve analysis.
At a fixed specificity (90%) of NNMT, the sensitivity was
59.1% and the correspondingAUCwas 0.900. Themedian
concentration of LCP1 in control individuals and patients
with kidney cancers was 10,384 and 13,789 pg/mL,
respectively; this difference was significant (P < 0.0001),
although the ratio ofmedian LCP1 concentration between
controls and patients was lower than that for NNMT. The
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www.aacrjournals.org Cancer Epidemiol Biomarkers Prev; 22(3) March 2013 393
on May 15, 2014. © 2013 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
plasma concentration of NM23A was also significantly
higher in patients with kidney tumor than in controls
(P < 0.0001), with amedian concentration of 780 and 3,442
pg/mL in control individuals and patients with kidney
cancer, respectively. When 90% specificity was defined,
the sensitivity of LCP1 andNM23Awas 73.9% and 54.6%,
respectively.
Composite marker of NNMT, LCP1, and NM23A
showed improved clinical performance
To evaluate the diagnostic performance of a composite
marker in a 3-plex assay, stepwise logistic regression
analysis was conducted for simultaneous assaying of
NNMT, LCP1, and NM23A. The predictive probability
was generated and used to estimate the diagnostic value
by ROC analysis. The diagnostic accuracy of logistic
regression with the composite marker was 0.904 (AUC)
and the sensitivity at fixed specificity (90%) was 71.6%.
Thus, when LCP1 and NM23Awere added to the NNMT
assay, the sensitivity and accuracy was improvedwith no
loss of specificity comparedwithNNMTalone (sensitivity
59.1%, AUC 0.900) or the other 2 markers used individ-
ually. To facilitate the use of composite marker, a simpli-
fied scoring method was applied to generate predictive
diagnostic values. As described previously, the cut-point
for each of the 3 markers was selected at the point of the
highest Youden Index using the data of 189 plasma sam-
ples. The cut-point ofNNMT, LCP1, andNM23Awas 147,
12,974, and 1,230 pg/mL, respectively. When the concen-
tration of the 3markerswas below the cut-point, a score of
0 was assigned; otherwise a score of 1 was assigned to the
subjects. Using the summed score of the 3 markers, the
diagnostic performance of composite marker was evalu-
atedwith thedata from189plasma samples of the training
group. The diagnostic accuracy of the score for composite
marker was 0.921 (AUC) and the sensitivity at fixed
specificity (90%) was 94.4%. Finally, blinded test group
samples including an additional 100plasma samples from
73 control individuals and 27 patients with kidney cancer
were applied to validate the clinical performance of com-
posite marker with the scoring method based on the cut-
point determined previously. In this blinded test group
analysis, the performance of composite markers was
found to be comparable with that of the training group
samples. Sixty-seven samples of 73 control individuals
and 27 samples of 27 patients with kidney cancer were
classified correctly. The resulting diagnostic characteris-
tics for the training group, test group, and overall 289
blind samples are summarized in Table 2. As a single
marker, NNMT showed the highest diagnostic perfor-
mance, with diagnostic accuracy (AUC) of 0.919 and
sensitivity of 71.9% at fixed specificity (90%). The
improved performance of NNMT, LCP1, and NM23A as
a composite marker was also validated. When 90% spec-
ificity was defined, the sensitivity of the 3-marker assay
with scoring was 95.7% and the diagnostic accuracy
(AUC) was 0.932. The predictive value of the 3-marker
assay with scoring was 87.2% (positive predictive value)
and 97% (negative predictive value). The relationship
between specificity and sensitivity of each marker or the
3-marker combination is shown in Fig. 2A and B.
The sensitivity of the 3-marker assay and the NNMT
assay was high for most of the RCC subtypes examined
(Table 3). For malignant tumors, the sensitivity of the 3-
marker assay with scoring ranged from 86% to 100%.
Although the specificity was reduced for benign tumors,
further extensive investigation is needed to determine
whether the 3-marker assay is able to differentiate
between malignant and benign kidney tumors, for exam-
ple, oncocytoma, to the similar extent of specificity with
control individuals without tumors.
Discussion
NNMT is a cytosolic protein that is mainly expressed in
the liver and catabolize xenobiotics (12). An association of
NNMTwith colorectal, thyroid, gastric, and bladder can-
cers has been reported (13–16) and its potential as a serum
marker was also suggested in colorectal and lung cancer
Figure 1. Plasma concentration of 3 markers measured with the 3-plex assay. A, the median level of NNMT was 6.2-fold higher in patients with kidney tumor
than in control individuals (control, 68 pg/mL; patients, 420 pg/mL); B, the level of LCP1 was 1.3-fold higher in kidney tumor patients (control, 10,384 pg/mL;
patients, 13,789 pg/mL); and C, the level of NM23A was 4.4-fold higher in patients with kidney tumor (control, 780 pg/mL; patients, 3,442 pg/mL).
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(15, 17). Furthermore, a recent study provided evidence
that elevated expression of NNMT in cells is correlated
with lower cell migration rates (13). Increasing evidence
for the association of NNMTwith cancer and its potential
as a cancer marker, support the role of NNMT as a
surrogate marker for RCC. Although elevated NNMT
expression has been reported in several cancers, the
actual expression level might differ between cancers.
In fact, our previous report showed significant differ-
ential expression of NNMT in several normal and can-
cer tissues including cervical, lung, liver, and ovarian
cancer (9): the normalized intensity of NNMT spots in 2-
dimensional gel electrophoresis gels of kidney, cervical,
lung, liver, and ovarian cancer was 2,976, 211, 298, 385,
and 235 units and that of corresponding normal tissue
was 162, 30, 93, 537, and 234 units, respectively. The
elevation of NNMT in kidney tumor was especially
prominent in comparison with several other cancer
tissues including liver, which is a source of NNMT. At
present, it is not clear why the expression of NNMT in
RCC is elevated to such an extent. In the present study,
we confirmed that cytosolic NNMT could be detected in
the periphery, and that its plasma concentration was
elevated 6.2-fold in patients with kidney cancer (P <
0.0001; Fig. 1A). The distribution of plasma concentra-
tion of NNMT is shown in Fig. 3A. There was some
overlap between NNMT plasma levels of control indi-
viduals and patients with kidney tumors, and it remains
to be determined whether this overlap originates from
abnormal expression of NNMT associated with other
unknown diseases in the patients without renal cancer
or from analytic nonspecificity of the assay.
Plastins belong to the class of actin-bundling proteins.
LCP1 expression is found in cells of the hematopoetic
lineage (leukocytes). Although LCP1 is the hematopoetic
isoform of the plastins, it is also expressed inmost human
cancer cell lines (18–20). However, the functional impor-
tance of LCP1 expression in tumor tissues is controversial
(20). Previous studies have shown that the expression
level of LCP1 correlated with tumor progression in colon
cancer (20–22) and that LCP1 overexpression might be
involved in prostate cancer invasion (23). However, no
such correlation was observed in breast carcinomas (24).
In the previous report (9) and the present study of kidney
tumors, LCP1 expression in tumors and the level of LCP1
in plasma of patients was correlated with all stages of
kidney tumor. As there is increasing evidence for a role of
LCP1 in cancer progression, LCP1 is also a promising
marker for RCC. NM23A (synonym of NM23-H1) was
identified through its reduced mRNA transcript levels in
Figure 2. ROC curve for the
relationship between speciﬁcity
and sensitivity of markers. A, ROC
curve for each of the 3 markers,
individual and in combination,
compared with logistic regression
or scoring method. B, dot plot of
ROC of the 3-marker combination
assay with scoring method.
Table 3. Sensitivity of NNMT and 3-marker combination in subtypes of kidney tumor
Sensitivity%
Speciﬁcity% Cell type
Marker Control Oncocytoma
Clear cell
carcinoma
Papillary
carcinoma
Chromophobe
carcinoma TCC
Unclassiﬁed
carcinoma
NNMT at cutoff >
147 pg/mL
84.6 (26/169) 50 (3/6) 93 (83/89) 100 (6/6) 86 (6/7) 100 (9/9) 100 (3/3)
NNMT, LCP1, NM23A
score at cut-off > 1
91.7 (14/169) 67 (2/6) 96 (85/89) 100 (6/6) 86 (6/7) 100 (9/9) 100 (3/3)
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highly metastatic cells (25). However, the functional rela-
tionship between NM23A and tumor progression or
metastasis, including renal tumors, is still controversial
(25–28). Levels of LCP1 and NM23A are elevated in all
subtypes of RCC (9), and the present study confirmed a
significant elevation of plasma LCP1 levels in patients
with RCC (LCP1, 1.3-fold; NM23A, 4.4-fold; P <
0.0001; Fig. 1B and C). The plasma concentration is pre-
sented as a distribution plot in Fig. 3B and C. A more
extended overlap between normal individuals and
patients with cancer was evident for LCP1 and NM23A,
which resulted in lower diagnostic performance
expressed as specificities, sensitivities, and AUCs of each
marker compared with NNMT (Table 2).
The 3-marker assay (3-plex) using scoring was highly
sensitive for all pathologic stages, and the NNMT assay
alone was comparable with the 3-marker assay (Table 4).
Fora stage I cohort, the sensitivityof the3-markerassayand
NNMT alone was 95% and 92%, respectively. The median
plasma concentration of NNMT, with respect to tumor
stage, was 377 pg/mL (stage Ia), 440 pg/mL (stage Ib),
694 pg/mL (stage II), 519 pg/mL (stage IIIa), 595pg/mL
(stage IIIb), and 1,461 pg/mL (stage IV). The correlation
between the plasma level of thesemarkers and tumor stage
should be further explored with an expanded population.
There was an overlap in the distribution of plasma
concentration of each of the 3 markers between normal
individuals and patients with kidney tumor. However,
Table 4. Speciﬁcity or sensitivity of NNMT and 3-marker combination in control individual and kidney
tumors according to its pathologic tumor stages
Sensitivity (%)
Speciﬁcity (%)
pT stage
Control Stage Ia/Ib Stage II Stage IIIa/IIIb Stage VI
NNMT at cut-off >
147 pg/mL
83.4 (29/175) 92 (54/59) 100 (13/13) 100 (29/29) 100 (2/2)
NNMT, LCP1, NM23A
Score at cut-off > 1
90.9 (16/175) 95 (56/59) 92 (12/13) 97 (28/29) 100 (2/2)
Figure 3. Distribution of plasma concentration ofmarkersmeasuredwith the 3-plex assay. Plasma distribution was represented byBox-andWhisker-plot. The
central box represents the values from the lower to upper quartile (25th–75th percentile). Themiddle line represents themedian. An outside value is deﬁned as
a value that is smaller than the lower quartileminus 1.5 times the interquartile range, or larger than the upper quartile plus 1.5 times the interquartile range (inner
fences). A far out value is deﬁned as a value that is smaller than the lower quartile minus 3 times the interquartile range, or larger than the upper quartile plus 3
times the interquartile range (outer fences). These values are plotted with a different marker.
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the 3-marker assay with NNMT, LCP1, and NM23A
improved sensitivity at a fixed specificity (Table 2). Vice
versa, at fixed sensitivity (95%), the specificity of NNMT
was 80.2% (95% CI, 67.4–87.4), whereas the specificity of
the 3-marker combination increased to 90.9% (95% CI,
77.6–96.0). Thus, the limitation of each single marker was
overcome with the 3-marker combination assay, leading
to improveddiagnostic accuracy (AUC, 0.932). The results
of the present clinical trial warrant validation of the 3-plex
composite marker assay including NNMT, LCP1, and
NM23A in a multicenter study.
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